TheraRadar
← Back
Data updated: Nov 8, 2026

Replimune, Inc.

Biotech
OncologyDermatology Execution: Needs Improvement

Replimune, Inc. is a biotechnology company focused on Oncology, Dermatology. Key products include TUDRIQEV.

2026
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Biologics

Replimune, Inc.'s Key Drugs

Replimune, Inc.'s core commercial portfolio centers on TUDRIQEV, spanning Oncology and Dermatology — its most strategically important drugs approved in the last 15 years.

TUDRIQEV
Approved 2026

Replimune, Inc.'s Recent FDA Approvals

Replimune, Inc. secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

TUDRIQEV BLA
2026-08-06
vusolimogene oderparepvec-wtpg

Replimune, Inc.'s Therapeutic Areas

Replimune, Inc.'s approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Dermatology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 90%
0 drugs Phase 3: 1 Phase 2: 6 Phase 1: 3
Dermatology 10%
0 drugs Phase 2: 1

Replimune, Inc.'s Top Competitors

Replimune, Inc.'s closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Oncology, Dermatology
Eli Lilly big-pharma
Oncology, Dermatology
Bayer big-pharma
Oncology, Dermatology
KING PHARMS big-pharma
Dermatology, Oncology
PAI HOLDINGS PHARM specialty
Dermatology, Oncology

Replimune, Inc. Pipeline Snapshot

Replimune, Inc. has 11 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 7 Phase 2 and 3 Phase 1.

1
Phase 3
7
Phase 2
3
Phase 1

Phase 3 Readout Calendar Pro

2 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q1 2029
Vusolimogene Oderparepvec
Advanced Melanoma
Estimated · aging NCT06264180
Q1 2030
RP2
Metastatic Uveal Melanoma
Estimated · aging NCT06581406

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • TUDRIQEV leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • 2 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/1 completed
  • • Speed: N/A months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges